Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-lo...
https://www.youtube.com/watch?v=xagrobF4q1k
Guggenheim analyst Seamus Fernandez reiterates Eli Lilly (NYSE:LLY) with a Buy and maintains $948 price target.
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 ...
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpointIn ACHIEV...
BERLIN, Oct. 13, 2025 /PRNewswire/ -- The WHO Foundation and Lilly have announced a collaboration to financially support the ai...
Eli Lilly and Company (NYSE:LLY) today announced that new data from across its oncology portfolio and pipeline will be presente...
